Leadership TeamExperienced, results-driven leadership
Experienced, result-driven leadership
The TherapeuticsMD management team has extensive experience and a proven track record of success in product innovation, development, and commercialization , including within the women's healthcare industry. We believe that our leadership's ability to leverage our robust intellectual property, product pipeline, and entrepeneurial spirit will continue to guide the company into a promising future.
Robert (Rob) G. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women’s health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing and intraoperative technical support. During his tenure at ESI, Rob advanced to a regional management role, eventually leaving to join Omnicell Technologies (OMCL), a leader in pharmacy automation. While at Omnicell, Rob served as a sales director, ultimately leaving the company to co-found CareFusion in 2001. CareFusion was a pioneer in hospital patient safety systems for Medication, Blood, and Specimen verification at the point of care. The company was successfully sold to Cardinal Health in 2006. Rob co-founded TherapeuticsMD (TXMD) in 2008, combining his background in women’s healthcare, pharmaceutical technology, clinical software, and patient safety. Today, TXMD is a leader in women’s health, pharmaceutical development, and commercialization. In 2011, Rob took TXMD public, with a current market capitalization of over a billion dollars. Since inception, Rob raised more than $500 million in capital and listed TXMD on the NYSE before transferring to the Nasdaq in 2017. Rob sits on the Board of Directors for two non-profit organizations, BioFlorida and the Boca Raton Police Foundation. Prior to his healthcare career, Rob, a University of Miami graduate who earned a Bachelor of Arts degree majoring in Premed and Psychology, taught English in Osaka, Japan.
John Milligan is President of TherapeuticsMD. An experienced, entrepreneurial healthcare executive, Mr. Milligan has more than 20 years of successful sales, management, business development, and operations experience. Throughout his career, he has leveraged his knowledge of the complex healthcare environment to create numerous successful companies. He co-founded clinical technology vendor CareFusion in 2001, selling it to Cardinal Health in 2006. Mr. Milligan held executive sales and operation management positions with Omnicell, Inc., a provider of clinical workflow solutions; Serving Software Inc.; and HBOC. McKesson Corporation eventually acquired the latter two companies. Mr. Milligan received his Bachelor of Science degree in Management Engineering from the United States Naval Academy.
Dan Cartwright is Chief Financial Officer at TherapeuticsMD. His 20 years of financial management experience includes serving as Chief Financial Officer in both the public and private sectors. In addition to his experience in healthcare, Mr. Cartwright worked in the finance, cable, and telecommunications industries. He has participated in several mergers and acquisitions, including those involving American Wireless Systems, Telegeography and WEB Corporation (Arush Entertainment). Before holding his CFO positions, Mr. Cartwright worked for KPMG and PricewaterhouseCoopers and was a Certified Public Accountant in Texas. He earned his Bachelor of Science degree in Accounting from Arizona State University.
Dawn Halkuff has held numerous senior level commercial and marketing positions over 20 years. Most recently, she was Senior Vice President of the Pfizer Consumer Healthcare Wellness Organization and a member of the Consumer Global Leadership Team. Ms. Halkuff was also commercial lead for sales and marketing of the Pfizer Women’s Health Division, focusing on the company’s reinvestment in hormone therapy treatment, including Premarin Vaginal Cream® and oral hot flash treatments. From 2005 to 2010, Ms. Halkuff was Head of Global Innovation at Weight Watchers International, where she created new weight-loss products, services, and solutions for women worldwide. She holds a BA in Psychology from University of Connecticut and an MBA from Pennsylvania State University.
Dr. Brian Bernick is Co-Founder and Director at TherapeuticsMD. Dr. Bernick is a practicing, board-certified obstetrician/gynecologist with over 20 years of clinical medical experience. Dr. Bernick currently serves on the American College of Obstetricians and Gynecologists’ (ACOG) national committee on Professional Liability. Dr. Bernick was the Department Chair of Obstetrics and Gynecology at Boca Raton Regional Hospital and served on that hospital’s Medical Executive Board as well as the Board of Directors of the Palm Beach Medical Society and VitalMD Group Holding, LLC, the largest physician-owned and managed obstetricians/gynecologists group in Florida. Dr. Bernick is the recipient of several national and regional awards, including recognition by his peers as one of the top doctor’s in his specialty by Castle Connolly as well as the recipient of the American Medical Association Foundation’s Leadership Award. Dr. Bernick has numerous publications in peer-reviewed journals as well as having presented original research at numerous medical conferences. Dr. Bernick holds 14 patents focusing on drug therapies and analysis. Dr. Bernick is an associate professor of Florida Atlantic University College of Medicine. Dr. Bernick holds a Bachelor of Arts degree in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residency at the University of Pennsylvania.
Dr. Sebastian Mirkin is Chief Medical Officer at TherapeuticsMD. Dr. Mirkin has more than 15 years of clinical development and medical affairs experience in women’s health. His experience includes Global Lead of Women’s Health Clinical Research at Pfizer; Senior Director Clinical Research, Women’s Health at Wyeth; and Global Lead Medical Services at Organon. Dr. Mirkin oversaw the development and successful marketing authorization of several novel medicines including Duavee®, Conbriza®, Lybrel® and Premarin® Vaginal Cream in the United States, Europe, and Japan. Dr. Mirkin holds a Doctor of Medicine degree from National University, Argentina. Trained in obstetrics/gynecology, Dr. Mirkin completed his fellowship in Reproductive Medicine at the Jones Institute of Reproductive Medicine in Norfolk, Virginia, and was involved in several NIH and pharmaceutical-sponsored clinical trials in reproduction, contraception, and menopausal health. Dr. Mirkin’s awards include the New Young Investigator Award from the North American Menopause Society and the Burroughs Fellowship Award from the Society for Gynecological Investigation. Published extensively in the fields of menopause, contraception, and reproductive endocrinology, Dr. Mirkin is an ad hoc reviewer for multiple women’s health-related journals.
Julia Amadio is Chief Product Officer at TherapeuticsMD. Ms. Amadio has an extensive 25+ year background in general management and in leading pharmaceutical marketing and product development organizations, including Johnson & Johnson, Wyeth, Rhone-Poulenc, Aventis, and Daiichi. Ms. Amadio earned her Bachelor of Science degree in Accounting from St. Joseph’s University and a Master of Business Administration degree from Drexel University. Ms. Amadio is an active member and leader in the Healthcare Businesswomen’s Association. She was an adjunct lecturer in the Pharmaceutical MBA program at St. Joseph’s University, and authored a chapter on marketing, market research, and insights in the book Pharmaceutical Development for Women, published by
Wiley & Sons.
Marlan Walker is General Counsel and Chief Development Officer at TherapeuticsMD. Previously, he was in-house IP counsel for Medicis Pharmaceutical Corporation, which was acquired by Valeant Pharmaceutical International in December 2012. In addition to his experience as an in-house attorney, Mr. Walker has extensive experience in private practice at a number of nationally recognized law firms. Mr. Walker’s particular expertise is in the life science industries, including long-term portfolio strategy and management, patent preparation and prosecution, contract negotiation and drafting, life-cycle management, and Hatch-Waxman. He received his Bachelor and Master of Science (Molecular Biology) degrees from Brigham Young University. Mr. Walker also received a Juris Doctor degree from the Arizona State University Sandra Day O’Connor College of Law and Master of Laws degree in intellectual property law from George Washington University Law School.
Eileen Farinacci is Chief Manufacturing Officer at TherapeuticsMD. Her 35+ years of experience in the pharmaceutical industry includes roles in manufacturing, quality assurance and control, and general management at Sterling Winthrop, Inc. and most recently at Bausch + Lomb. At Sterling Winthrop, Ms. Farinacci was head of the company’s largest manufacturing site, overseeing a vertically integrated, multi-plant compound that included the manufacturing of APIs and multiple pharmaceutical dosage forms. At Bausch + Lomb, she was Vice President of Operations for all US pharmaceutical manufacturing. In addition to her roles in manufacturing and quality assurance and control, Ms. Farinacci held general management positions with full P&L responsibility at Bausch + Lomb in Canada, Latin America, and most recently Southern Europe. Ms. Farinacci holds a Bachelor of Science Degree in Pharmacy from the University of Puerto Rico.
Mitchell Krassan is Chief Strategy & Performance Officer at TherapeuticsMD. He has 25 years of operational and financial management experience. Prior to joining TherapeuticsMD, Mr. Krassan was a principal in EquiMark Limited, a private investment company that provided its portfolio companies with resources in the form of executive management, marketing and financial operations. Earlier on, Mr. Krassan was Chief Financial Officer and Chief Operations Officer of The Reich Group, a fully integrated direct marketing company with a focus on strategic planning, research, and operations. Mr. Krassan started his career in the big six public accounting where he rose to the level of manager at Arthur Andersen, focusing on operational consulting for closely held companies. Mr. Krassan received his Bachelor of Science degree in Accounting from the University of Maryland and his Master of Business Administration in Management from New York University.
Jason Spitz is Vice President of Commercial Development & Operations at TherapeuticsMD. Mr. Spitz has over 25 years of marketing, advertising, and general management experience in the pharmaceutical and biopharmaceutical markets. Prior to TherapeuticsMD, Mr. Spitz was Managing Director, Oncology & Hematology at Beacon Healthcare Communications. Mr. Spitz began his career at Schering-Plough Pharmaceuticals as a sales representative, rising within the organization over 15 years to lead a global pharmaceutical franchise. He also held senior commercial leadership roles at Aesgen, Inc. and MGI Pharma, Inc. (acquired by Eisai, Inc.). Mr. Spitz received his Bachelor of Business Administration in Marketing from the University of Texas at Austin and his Master of Business Administration in Pharmaceutical Studies from Fairleigh Dickinson University.
Christian Bloomgren is Vice President of Sales at TherapeuticsMD. Mr. Bloomgren has 16 years of leadership experience in the pharmaceutical, biotechnology, and diagnostic industries. Prior to TherapeuticsMD, Mr. Bloomgren was on the management team at ViaCell, Inc., acquired by PerkinElmer, creating a successful national sales channel and later leading the Specialty Diagnostics business. Prior pharmaceutical experience includes women’s health product launch and sales management roles at Eli Lilly & Company and KV Pharmaceutical. Mr. Bloomgren served as an Officer in the United States Air Force and earned a Bachelor of Science degree from California State University and a Master of Science degree from
Troy State University.
Michael Donegan is Vice President of Finance at TherapeuticsMD. He has served in this role since April 2013. Mr. Donegan has a 26-year background in accounting and finance. He has spent a great portion of his career focused on accounting/finance infrastructure and compliance. Mr. Donegan has spent much of the last decade designing and implementing Sarbanes-Oxley 404 compliance programs for companies of all sizes. He has also had numerous responsibilities at large public companies in corporate finance/accounting roles that include finance systems, global consolidations, and SEC reporting. Mr. Donegan began his career at Ernst & Young, LLP, where he worked in both the audit and tax departments. Mr. Donegan has written and spoken on the topic of finance infrastructure and its impact on financial reporting, having authored Growth and Profitability: Optimizing the Finance Function for Small and Emerging Businesses (Copyright © 2002 by John Wiley and Sons, Inc. All rights reserved). Mr. Donegan earned his Bachelor of Science in Accounting and his Master of Accounting from the University of Florida.